Clinical Commander

Back to dossier
cardio.cardiac-tamponade.tb-pericarditis.v1PRODUCTION
cardio.cardiac-tamponade.tb-pericarditis.v1

Cardiac tamponade — tuberculous pericarditis

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

9/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Tuberculous tamponade — pericardiocentesis for diagnosis + tamponade relief; 4-drug RIPE anti-TB therapy is the curative pathway; adjunctive steroids only in HIV-NEGATIVE per IMPI; ~25% develop constrictive pericarditis requiring pericardiectomy (ESC 2015; Mayosi NEJM 2014 PMID 25199187)

Inputs
1
Actions
0
Advance rule
Set
Advance when

TB-context tamponade physiology suspected

Patient inputs (10)

Age modifies HIV co-infection probability + drug interaction profile + steroid risk-benefit (WHO TB 2024)

Compensatory tachycardia in tamponade physiology (ESC 2015)

Universal HIV testing in suspected TB pericarditis (WHO 2024); CD4 count drives steroid decision (IMPI subgroup PMID 25199187 — KS risk in HIV+ on steroids); also drives ART timing per WHO IRIS guidance

Endemic region, prior TB, healthcare worker, immunocompromise, contacts — drives pre-test probability (WHO 2024)

Fever is a key constitutional symptom of TB; pattern + height inform clinical suspicion (ESC 2015 §Tuberculous Pericarditis; Mayosi Heart 2017)

Definitive bedside dx — chamber collapse, IVC, swinging heart; fibrin strands and loculations characteristic of TB etiology (ESC 2015 Class I)

Baseline for ethambutol + RIPE drug dose-adjustment + nephrotoxicity surveillance (WHO TB 2024)

Baseline for RIPE-induced hepatitis surveillance — INH/RIF/PZA all hepatotoxic (WHO TB 2024 — discontinue if ALT >5x ULN or symptomatic)

CXR or chest CT for active pulmonary TB (cavitation, infiltrates, mediastinal lymphadenopathy); positive findings strengthen TB pericarditis dx + indicate isolation (WHO 2024)

Hypotension is part of Beck triad; pulsus paradoxus measurement (Spodick Circulation 2003)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningdrug_induced_hepatitis_from_ripe
    ALT >5x ULN OR symptomatic hepatitis (jaundice, RUQ pain, nausea) on RIPE — most commonly INH/RIF/PZA hepatotoxicity (WHO TB 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningmdr_tb_resistance_requiring_regimen_change
    Xpert MTB/RIF or culture susceptibility shows resistance to rifampin (RR-TB) or rifampin + INH (MDR-TB) — standard 6-mo RIPE inadequate (WHO 2024 MDR-TB guidelines)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverehiv_co_infection_management_with_iris_risk
    HIV+ patient with TB pericarditis requiring ART optimization with IRIS-aware timing (WHO HIV/TB coinfection 2024; Mayosi IMPI subgroup PMID 25199187)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereconstrictive_pericarditis_development_at_6_mo
    Constrictive pericarditis physiology developing during or after RIPE completion — ~25% of TB pericarditis develop constriction requiring pericardiectomy (ESC 2015 Class IIa; Mayosi Heart 2017)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereiris_paradoxical_worsening_in_hiv_pt_on_art
    Worsening pericardial disease 2-8 wk after ART initiation in HIV+ TB pericarditis pt — paradoxical IRIS reaction (WHO 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Tuberculous pericarditis — pericardiocentesis + 4-drug RIPE × 6 mo + selective adjunctive prednisolone in HIV-NEGATIVE only (ESC 2015; WHO 2024; IMPI Mayosi NEJM 2014 PMID 25199187)
axis: tuberculous_pericardial_ripe_plus_drainage_plus_selective_steroid
Selected axis "Tuberculous pericarditis — pericardiocentesis + 4-drug RIPE × 6 mo + selective adjunctive prednisolone in HIV-NEGATIVE only (ESC 2015; WHO 2024; IMPI Mayosi NEJM 2014 PMID 25199187)" by default fallback (first axis)
  • rifampin
    first line
    antimycobacterial_rifamycin
    10 mg/kg PO daily (max 600 mg) • PO • daily × 2 mo intensive + 4 mo continuation
    triggers: confirmed_or_high_probability_tb_pericarditis
    WHO 2024 — first-line anti-TB; CYP450 inducer requiring drug interaction review (especially ART, anticoagulants, contraceptives); orange-colored body fluids
    rxcui 9384
  • isoniazid
    first line
    antimycobacterial_inh
    5 mg/kg PO daily (max 300 mg) + pyridoxine 25-50 mg daily • PO • daily × 6 mo total
    triggers: confirmed_or_high_probability_tb_pericarditis
    WHO 2024 — first-line; pyridoxine prevents peripheral neuropathy; hepatotoxicity surveillance
    rxcui 6038
  • pyrazinamide
    first line
    antimycobacterial_pza
    25 mg/kg PO daily (max 2000 mg) • PO • daily × 2 mo intensive only
    triggers: confirmed_or_high_probability_tb_pericarditis
    WHO 2024 — intensive phase only; hyperuricemia + hepatotoxicity surveillance; renal dose-adjust
    rxcui 8987
  • ethambutol
    first line
    antimycobacterial_emb
    15-25 mg/kg PO daily (max 1600 mg) • PO • daily × 2 mo intensive (continue if drug-resistance)
    triggers: confirmed_or_high_probability_tb_pericarditis
    WHO 2024 — intensive phase; visual acuity + color discrimination monitoring monthly (optic neuritis risk)
    rxcui 4110
  • prednisolone
    add on
    corticosteroid
    60 mg PO daily × 4 wk then taper × 6 wk per IMPI • PO • daily × 4 wk full + 6 wk taper
    triggers: hiv_negative_tb_pericarditis_for_constriction_prevention
    IMPI trial (Mayosi NEJM 2014 PMID 25199187) — reduced constrictive pericarditis risk in HIV-NEGATIVE; NO mortality benefit; AVOID in HIV+ (increased KS risk in IMPI subgroup)
    rxcui 8638
  • pyridoxine
    add on
    vitamin_b6
    25-50 mg PO daily • PO • daily concurrent with INH
    triggers: inh_co_administration_to_prevent_peripheral_neuropathy
    Prevents INH-induced peripheral neuropathy; standard with all INH-containing regimens (WHO 2024)
    rxcui 684879
  • normal saline
    first line
    isotonic_crystalloid
    500-1000 mL bolus • IV • rapid bolus then reassess
    triggers: hypotension_pre_drainage
    Bridge preload to drainage (ESC 2015)
    rxcui 9863
  • norepinephrine
    rescue
    vasopressor
    0.05-0.1 µg/kg/min titrate to MAP ≥65 • IV • continuous
    triggers: SBP_lt_85_despite_fluids
    Bridge only — does not address obstruction (Roy JAMA 2007)
    rxcui 7512

outpatient playbook — drug actions (4)

  1. 1. continue RIPE continuation phase × 4 mo
    rxcui 9384
    rifampin 600 mg + INH 300 mg + pyridoxine 25 mg PO daily • PO • daily
    trigger: Continuation phase post-intensive
    WHO 2024 — 4 mo continuation completes 6-mo course
  2. 2. completion of RIPE at 6 mo + final cure documentation
    completed; cure documentation • N/A • completed
    trigger: End of 6-mo RIPE course
    WHO 2024 — extend to 9 mo if drug resistance or treatment failure
  3. 3. ART maintenance in HIV+
    per regimen • PO • per regimen
    trigger: HIV+ ongoing
    WHO HIV — lifelong adherence + viral suppression
  4. 4. diuretic for constriction symptoms if developing
    rxcui 4603
    furosemide 20-40 mg PO daily titrate • PO • daily
    trigger: Constriction symptoms developing
    Symptomatic relief while pericardiectomy evaluated (ESC 2015)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Subacute (days-weeks) dyspnea + fever + weight loss + night sweats + Beck triad in patient with TB risk factors (endemic region, HIV+, prior TB, healthcare worker) → tuberculous tamponade (ESC 2015 §Tuberculous Pericarditis; Mayosi Heart 2017); Echo: pericardial effusion (often large >2 cm) with fibrin strands or septations + RV diastolic collapse + IVC plethora in patient with TB risk factors (ESC 2015); HIV+ patient (especially sub-Saharan Africa, India) presenting with new pericardial effusion — TB pericarditis is leading cause of pericardial disease in this population (Mayosi NEJM 2014 IMPI PMID 25199187; Sliwa).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — tuberculous pericarditis** (cardio.cardiac-tamponade.tb-pericarditis.v1).
Phenotype framing: Pericardial fluid analysis: ADA >40 U/L (sensitivity 88%, specificity 83%), IGRA on fluid, Xpert MTB/RIF on fluid, AFB stain + culture, cell count (lymphocytic exudate >50% lymphs), glucose (low), LDH (high), protein (high); pericardial biopsy GOLD STANDARD with culture + histology + Xpert (ESC 2015; Burgess Chest 2002; Reuter EHJ 2006)
Scope: Tuberculous tamponade — pericardiocentesis for diagnosis + tamponade relief; 4-drug RIPE anti-TB therapy is the curative pathway; adjunctive steroids only in HIV-NEGATIVE per IMPI; ~25% develop constrictive pericarditis requiring pericardiectomy (ESC 2015; Mayosi NEJM 2014 PMID 25199187)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Tuberculous pericarditis — pericardiocentesis + 4-drug RIPE × 6 mo + selective adjunctive prednisolone in HIV-NEGATIVE only (ESC 2015; WHO 2024; IMPI Mayosi NEJM 2014 PMID 25199187)**.
1. rifampin 10 mg/kg PO daily (max 600 mg) PO daily × 2 mo intensive + 4 mo continuation (antimycobacterial_rifamycin, first line) — WHO 2024 — first-line anti-TB; CYP450 inducer requiring drug interaction review (especially ART, anticoagulants, contraceptives); orange-colored body fluids
2. isoniazid 5 mg/kg PO daily (max 300 mg) + pyridoxine 25-50 mg daily PO daily × 6 mo total (antimycobacterial_inh, first line) — WHO 2024 — first-line; pyridoxine prevents peripheral neuropathy; hepatotoxicity surveillance
3. pyrazinamide 25 mg/kg PO daily (max 2000 mg) PO daily × 2 mo intensive only (antimycobacterial_pza, first line) — WHO 2024 — intensive phase only; hyperuricemia + hepatotoxicity surveillance; renal dose-adjust
4. ethambutol 15-25 mg/kg PO daily (max 1600 mg) PO daily × 2 mo intensive (continue if drug-resistance) (antimycobacterial_emb, first line) — WHO 2024 — intensive phase; visual acuity + color discrimination monitoring monthly (optic neuritis risk)
5. prednisolone 60 mg PO daily × 4 wk then taper × 6 wk per IMPI PO daily × 4 wk full + 6 wk taper (corticosteroid, add on) — IMPI trial (Mayosi NEJM 2014 PMID 25199187) — reduced constrictive pericarditis risk in HIV-NEGATIVE; NO mortality benefit; AVOID in HIV+ (increased KS risk in IMPI subgroup)
6. pyridoxine 25-50 mg PO daily PO daily concurrent with INH (vitamin_b6, add on) — Prevents INH-induced peripheral neuropathy; standard with all INH-containing regimens (WHO 2024)
7. normal saline 500-1000 mL bolus IV rapid bolus then reassess (isotonic_crystalloid, first line) — Bridge preload to drainage (ESC 2015)
8. norepinephrine 0.05-0.1 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor, rescue) — Bridge only — does not address obstruction (Roy JAMA 2007)

Setting playbook (outpatient) — Long-term surveillance for constrictive pericarditis (~25% develop); RIPE completion at 6 mo; pericardiectomy if constriction develops; HIV/ART continuation if applicable (ESC 2015; WHO 2024; Mayosi PMID 25199187)
9. continue RIPE continuation phase × 4 mo rifampin 600 mg + INH 300 mg + pyridoxine 25 mg PO daily PO daily — Continuation phase post-intensive (WHO 2024 — 4 mo continuation completes 6-mo course)
10. completion of RIPE at 6 mo + final cure documentation completed; cure documentation N/A completed — End of 6-mo RIPE course (WHO 2024 — extend to 9 mo if drug resistance or treatment failure)
11. ART maintenance in HIV+ per regimen PO per regimen — HIV+ ongoing (WHO HIV — lifelong adherence + viral suppression)
12. diuretic for constriction symptoms if developing furosemide 20-40 mg PO daily titrate PO daily — Constriction symptoms developing (Symptomatic relief while pericardiectomy evaluated (ESC 2015))

Non-pharmacologic actions:
- ID follow-up monthly during continuation phase then annually post-completion
- Cardiology follow-up at 3, 6, 12 mo then annually for first 5 yr (constriction surveillance)
- HIV care follow-up per regimen
- Cardiothoracic surgery referral if constriction physiology develops (~25%)
- Public health TB program completion documentation
- Patient + family education ongoing for adherence + recurrence recognition

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain (ESC 2015)
- Steroids_AVOID_in_HIV_positive_KS_risk_per_IMPI_subgroup (Mayosi NEJM 2014 PMID 25199187)
- Rifampin_significant_drug_interactions_review_ART_anticoagulants_contraceptives (WHO TB 2024)
- Pyrazinamide_hold_if_acute_gout_or_severe_hepatotoxicity (drug label)
- Ethambutol_hold_if_visual_changes_or_color_discrimination_loss (drug label)
- Isoniazid_hold_if_alt_gt_5x_uln_or_symptomatic_hepatitis (WHO 2024)
- Steroids_REQUIRE_HIV_test_first_negative_status_confirmed (IMPI PMID 25199187)
- Pyrazinamide_avoid_severe_renal_impairment_dose_adjust_per_egfr (WHO TB 2024)
- Colchicine_NOT_recommended_TB_etiology_no_evidence_potential_drug_interactions (ESC 2015)
- NSAIDs_use_caution_with_RIPE_hepatotoxicity_overlap (drug label)

Monitoring

Regimen monitoring:
- continuous ECG during drainage (ESC 2015)
- art line BP pre and post (Adler 2015)
- echo post drain immediate then q24 48h x 7d then weekly then per RIPE response
- fluid analysis ada igra xpert afb culture cytology cell count glucose ldh protein (ESC 2015; Reuter EHJ 2006; Burgess Chest 2002)
- pericardial biopsy results culture histology xpert gold standard (ESC 2015)
- LFTs baseline then q2-4 wk during intensive phase then monthly (WHO 2024 — RIPE hepatotoxicity)
- serum creatinine baseline then monthly (WHO 2024 — ethambutol/PZA dose adjustment)
- visual acuity color discrimination monthly for ethambutol (WHO 2024)
- serum uric acid baseline then per symptoms for PZA hyperuricemia (WHO 2024)
- hiv test result CD4 count to inform steroid decision and ART timing (Mayosi PMID 25199187; WHO 2024)
- CRP q4 wk for treatment response (Mayosi Heart 2017)
- serial echo for constriction surveillance at 3 6 12 mo (ESC 2015)
- sputum AFB smear culture for isolation decision (WHO 2024)
- contact screening per public health TB program (WHO 2024)

Setting (outpatient) monitoring:
- Echo at 3, 6, 12 mo then annually × 5 yr
- CMR + RH cath if constriction physiology suspected
- CRP per follow-up
- HIV viral load + CD4 q3-6 mo if HIV+

Monitoring phase: Re-accumulation surveillance (echo q24-48h initially then weekly then per follow-up); RIPE drug toxicity monitoring (LFTs q2-4 wk for first 2 mo, visual acuity for ethambutol, hyperuricemia for PZA); CRP trend; constriction surveillance with serial echo + RH cath if symptoms (ESC 2015; WHO 2024)

Disposition

Current setting: outpatient — Long-term surveillance for constrictive pericarditis (~25% develop); RIPE completion at 6 mo; pericardiectomy if constriction develops; HIV/ART continuation if applicable (ESC 2015; WHO 2024; Mayosi PMID 25199187)

Disposition criteria:
- Long-term continuation under multidisciplinary team; pericardiectomy if constriction develops; cross-link to cardio.cardiac-tamponade.core.v1 for acute recurrence pathway

Escalation triggers (move to higher acuity):
- Symptomatic constrictive pericarditis (NYHA II-IV symptoms with constrictive physiology on imaging) → cardiothoracic surgery for pericardiectomy (Class IIa per ESC 2015)
- Recurrent effusion → re-drainage + diagnostic reconsideration (treatment failure? MDR-TB? other etiology?)
- TB recurrence (cough + sputum AFB+ + new constitutional symptoms) → ID + repeat workup + DOT re-engagement
- IRIS late presentation in HIV+ → ID + HIV team
- Effusive-constrictive pattern post-drainage → CMR + cardiothoracic for pericardiectomy evaluation

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] ALT >5x ULN OR symptomatic hepatitis (jaundice, RUQ pain, nausea) on RIPE — most commonly INH/RIF/PZA hepatotoxicity (WHO TB 2024)
- [LIFE_THREATENING] Xpert MTB/RIF or culture susceptibility shows resistance to rifampin (RR-TB) or rifampin + INH (MDR-TB) — standard 6-mo RIPE inadequate (WHO 2024 MDR-TB guidelines)
- [SEVERE] HIV+ patient with TB pericarditis requiring ART optimization with IRIS-aware timing (WHO HIV/TB coinfection 2024; Mayosi IMPI subgroup PMID 25199187)

Citations

- 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Tuberculous Pericarditis — remains current as of 2026-05-15. IMPI trial (Mayosi NEJM 2014 PMID 25199187) anchors adjunctive steroid decision (HIV-negative benefit, HIV+ harm); WHO Global TB Report 2024 + WHO TB treatment guidelines 2024 anchor 4-drug RIPE regimen and MDR-TB management; Mayosi Heart 2017 + Sliwa BM tuberculous heart disease in HIV anchor multidisciplinary co-management framework. [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 25199187) [PMID:25199187](https://pubmed.ncbi.nlm.nih.gov/25199187/)
- Cited evidence (PMID 17456823) [PMID:17456823](https://pubmed.ncbi.nlm.nih.gov/17456823/)
- Cited evidence (PMID 20656240) [PMID:20656240](https://pubmed.ncbi.nlm.nih.gov/20656240/)
- Cited evidence (PMID 12122206) [PMID:12122206](https://pubmed.ncbi.nlm.nih.gov/12122206/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Tuberculous Pericarditis — remains current as of 2026-05-15. IMPI trial (Mayosi NEJM 2014 PMID 25199187) anchors adjunctive steroid decision (HIV-negative benefit, HIV+ harm); WHO Global TB Report 2024 + WHO TB treatment guidelines 2024 anchor 4-drug RIPE regimen and MDR-TB management; Mayosi Heart 2017 + Sliwa BM tuberculous heart disease in HIV anchor multidisciplinary co-management framework. — PMID:26320112
  • Cited evidence (PMID 25199187) — PMID:25199187
  • Cited evidence (PMID 17456823) — PMID:17456823
  • Cited evidence (PMID 20656240) — PMID:20656240
  • Cited evidence (PMID 12122206) — PMID:12122206